SCA Pharmaceuticals Receives FDA Warning Letter Citing Sterile Compounding CGMP Failures at 503B Facility

Sterility assurance failures at a registered 503B outsourcing facility have drawn a formal FDA Warning Letter, signaling continued agency pressure on compounders operating under 21 CFR Parts 210 and 211. SCA Pharmaceuticals, LLC, based in Little Rock, Arkansas, received Warning Letter WL #724202 on September 14, 2026, following an inspection conducted October 20–30, 2025, that uncovered systemic aseptic processing deficiencies.

The FDA investigator documented four categories of violation. ISO 5 classified areas lacked routine certification and airflow visualization studies performed under dynamic conditions, a foundational requirement for sterility assurance programs. Separately, microbial contamination recovered within the aseptic processing zone was not followed by adequate product evaluation or corrective action, raising direct questions about the facility's CAPA infrastructure under 21 CFR Part 211.192.

Component control deficiencies compounded the picture: foreign material was identified between the stopper ribs of syringes, indicating inadequate incoming material inspection and product-contact surface controls. The fourth citation addressed aseptic technique directly, with compounding technicians and aseptic assistants observed employing practices that introduced microbial contamination risk into critical zones during production of sterile drug products, including Fentanyl Citrate 2 mcg/mL with Bupivacaine HCl 0.125%.

SCA Pharmaceuticals submitted responses to the Form FDA 483 on November 21 and December 31, 2025. FDA reviewed both submissions and found them insufficient to resolve the cited violations, proceeding to formal Warning Letter issuance. The facility has held 503B outsourcing registration since December 2013, with its most recent renewal filed December 5, 2025.

For QA directors at 503B facilities, the citation pattern here reflects enforcement priorities FDA has signaled repeatedly: dynamic airflow qualification, contamination event investigation depth, and observable aseptic behavior during production are active inspection focal points. Facilities that treat ISO classification as a periodic checkbox rather than a continuously validated state remain exposed.

Resolution of the Warning Letter will require SCA Pharmaceuticals to demonstrate corrective actions sufficient to satisfy CDER, with the adequacy of those responses determining whether further enforcement escalation follows.

Source: FDA Center for Drug Evaluation and Research (CDER) via FDA.gov Warning Letters database, September 14, 2026; inspection period October 20–30, 2025.